Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and magrolimab combination showed good overall response rate and an improved response duration as a frontline AML treatment for those ineligible for intensive chemotherapy. These results were particularly striking for patients with TP53 mutations, which often have poor response to traditional therapies. Dr Daver mentions current studies of triplet therapy using magrolimab with traditional azacitidine plus venetoclax.